Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, has announced an agreement to acquire IFF Pharma Solutions, a producer of excipients for oral dosage solutions. This acquisition will strengthen Roquette's position in the pharmaceutical industry, expanding its product range and accelerating growth. The deal is expected to close in the first half of 2025, pending regulatory approval. Roquette's CEO sees this as a strategic move to become a global specialist in drug delivery solutions. IFF's CEO views the partnership as an opportunity for growth and innovation. Both companies are excited about the potential for collaboration and future success in the health and nutrition markets.
La Madeleine (France) – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, announced today an agreement to acquire IFF Pharma Solutions, a worldwide producer of excipients for oral dosage solutions, to reinforce its position as a major partner to the pharmaceutical industry.
The combination of the two complementary businesses will rebalance the company’s portfolio around the two pillars of Health and Nutrition. It will expand its pharma product range and significantly accelerate Roquette’s growth.
IFF is headquartered in New York (USA). Its pharmaceutical division is a world-class producer of excipients for oral dosage solutions, with revenues of approximately $1B, 10 research and development and/or production sites globally, and around 1,100 employees. It has an extensive range of high-quality products, established brands and a client base of major pharmaceutical, food and nutraceutical companies around the world.
The acquisition of IFF Pharma Solutions is a transformative strategic step for Roquette. It expands its position in the attractive excipients market which benefits from strong fundamentals and outstanding growth prospects. It enhances Roquette’s US footprint, and it significantly expands its industry-leading formulation capabilities and drug delivery research and development. It turns the company into the pharmaceutical industry’s partner of choice for the development of innovative drug delivery solutions to best address current and future customer needs, and to improve patients’ lives.
Roquette and IFF target to close the transaction in the first half of 2025. Closing remains subject to regulatory clearance and satisfaction of other customary closing conditions.
Pierre Courduroux, Roquette CEO, said: “After last year’s acquisition of Qualicaps, today’s announcement is a decisive step in our journey to reinforce our position in the health and nutrition markets. The combination of our excipients’ expertise with IFF Pharma Solutions is a fantastic opportunity to become a true global specialist in drug delivery and oral dosage solutions. This responds to the needs of customers and patients looking for continuously better treatments. We very much look forward to welcoming IFF Pharma Solutions, and to jointly building the next chapter of our company’s growth history.”
Erik Fyrwald, IFF CEO, added: “We are pleased to reach an agreement with Roquette that will support Pharma Solutions’ next chapter of growth as a trusted partner for the pharmaceutical industry. This represents a great opportunity for our team and customers. Roquette is the ideal strategic partner for IFF Pharma Solutions, with whom it has complementary portfolio and innovation capabilities, and with whom it shares a culture of operational excellence.”